Real time insider trading transaction history:
- Insiders are prohibited from making short-swing profits by trading their shares within 6 months of the registration or acquiring the shares.
- Shares are not adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
Common stock purchase or sale:
| Transaction Date | Reported DateTime | Company | Symbol | Insider Relationship | Shares Traded | Average Price | Total Amount | Shares Owned | Filing |
| 2024-04-25 Sale | 2024-04-29 6:50 pm | Enliven Therapeutics Inc. | ELVN | Kintz Samuel PRESIDENT AND CEO | 12,000 | $16.89 | $202,700 | 1,465,428 (Indirect Direct) | View |
| 2024-04-11 Sale | 2024-04-15 7:06 pm | Enliven Therapeutics Inc. | ELVN | Patel Anish CHIEF OPERATING OFFICER | 17,500 | $25.03 | $438,099 | 454,744 (Indirect Direct) | View |
| 2024-04-11 Sale | 2024-04-15 7:06 pm | Enliven Therapeutics Inc. | ELVN | Lyssikatos Joseph P CHIEF SCIENTIFIC OFFICER | 30,000 | $25.04 | $751,332 | 1,347,585 (Indirect Direct) | View |
| 2024-04-11 Sale | 2024-04-15 7:05 pm | Enliven Therapeutics Inc. | ELVN | Kintz Samuel PRESIDENT AND CEO | 47,709 | $25.04 | $1,194,700 | 1,477,428 (Indirect Direct) | View |
| 2024-04-11 Sale | 2024-04-15 7:04 pm | Enliven Therapeutics Inc. | ELVN | Hohl Benjamin CHIEF FINANCIAL OFFICER | 14,000 | $24.72 | $346,149 | 225,370 (Direct) | View |
| 2024-04-11 Sale | 2024-04-15 7:03 pm | Enliven Therapeutics Inc. | ELVN | Heyman Richard A. Director | 6,964 | $24.11 | $167,888 | 203,129 (Indirect Direct) | View |
| 2024-04-11 Sale | 2024-04-15 7:02 pm | Enliven Therapeutics Inc. | ELVN | Collins Helen Louise CHIEF MEDICAL OFFICER | 20,000 | $25.07 | $501,478 | 267,084 (Direct) | View |
| 2024-04-10 Sale | 2024-04-12 6:23 pm | Enliven Therapeutics Inc. | ELVN | Ballal Rahul D. Director | 67,000 | $23.36 | $1,564,812 | 146,903 (Direct) | View |
| 2024-04-08 Sale | 2024-04-10 8:35 pm | Enliven Therapeutics Inc. | ELVN | Patel Anish CHIEF OPERATING OFFICER | 4,875 | $18.6 | $90,687 | 396,624 (Indirect Direct) | View |
| 2024-04-04 Sale | 2024-04-08 8:40 pm | Enliven Therapeutics Inc. | ELVN | Ballal Rahul D. Director | 3,485 | $19.15 | $66,729 | 84,761 (Direct) | View |
| 2024-04-01 Sale | 2024-04-03 9:32 pm | Enliven Therapeutics Inc. | ELVN | Ballal Rahul D. Director | 3,237 | $19.08 | $61,758 | 104,674 (Direct) | View |
| 2024-04-01 Sale | 2024-04-03 9:30 pm | Enliven Therapeutics Inc. | ELVN | Lyssikatos Joseph P CHIEF SCIENTIFIC OFFICER | 12,000 | $18.6 | $223,146 | 1,377,585 (Indirect Direct) | View |
| 2024-03-27 Sale | 2024-03-29 5:59 pm | Enliven Therapeutics Inc. | ELVN | Hohl Benjamin CHIEF FINANCIAL OFFICER | 3,250 | $18.25 | $59,302 | 239,370 (Direct) | View |
| 2024-03-25 Sale | 2024-03-27 5:03 pm | Enliven Therapeutics Inc. | ELVN | Kintz Samuel PRESIDENT AND CEO | 12,000 | $17.56 | $210,661 | 1,525,137 (Indirect Direct) | View |
| 2024-03-20 Sale | 2024-03-22 7:46 pm | Enliven Therapeutics Inc. | ELVN | Ballal Rahul D. Director | 13,278 | $19.16 | $254,462 | 41,912 (Direct) | View |
| 2024-03-19 Sale | 2024-03-21 6:41 pm | Enliven Therapeutics Inc. | ELVN | Heyman Richard A. Director | 1,270 | $14.5 | $18,419 | 210,093 (Indirect Direct) | View |
| 2024-03-06 Sale | 2024-03-08 7:52 pm | Enliven Therapeutics Inc. | ELVN | Patel Anish CHIEF OPERATING OFFICER | 4,875 | $15.64 | $76,239 | 401,499 (Indirect Direct) | View |
| 2024-02-29 Sale | 2024-03-04 5:55 pm | Enliven Therapeutics Inc. | ELVN | Lyssikatos Joseph P CHIEF SCIENTIFIC OFFICER | 12,000 | $16.42 | $197,006 | 1,389,585 (Indirect Direct) | View |
| 2024-02-27 Sale | 2024-02-29 5:27 pm | Enliven Therapeutics Inc. | ELVN | Hohl Benjamin CHIEF FINANCIAL OFFICER | 3,250 | $16.97 | $55,163 | 242,620 (Direct) | View |
| 2024-02-26 Sale | 2024-02-28 5:14 pm | Enliven Therapeutics Inc. | ELVN | Kintz Samuel PRESIDENT AND CEO | 12,000 | $16.89 | $202,653 | 1,537,137 (Indirect Direct) | View |
| 2024-02-15 Sale | 2024-02-20 7:41 pm | Enliven Therapeutics Inc. | ELVN | Heyman Richard A. Director | 1,270 | $17.42 | $22,117 | 211,363 (Indirect Direct) | View |
| 2024-02-14 Sale | 2024-02-16 4:15 pm | Enliven Therapeutics Inc. | ELVN | 5AM Partners VI LLC 5AM Ventures VI L.P. 5AM Opportunities I (GP) LLC 5AM Opportunities I L.P. PARMAR KUSH Schwab Andrew J. 10% Owner | 825,000 | $14.9 | $12,292,500 | 635,341 (Indirect) | View |
Stock options: Exercise, Award, Grant, Conversion
| Transaction Date | Reported DateTime | Exercisable Expiration | Company | Symnbol | Insider Relationship | Shares Traded | Conversion Price | Shares Owned | Filing |
| 2024-04-25 Exercise | 2024-04-29 6:50 pm | N/A 2030-06-16 | Enliven Therapeutics Inc. | ELVN | Kintz Samuel PRESIDENT AND CEO | 12,000 | $0 | 1,465,428 (Direct) | View |
| 2024-04-25 Exercise | 2024-04-29 6:50 pm | N/A N/A | Enliven Therapeutics Inc. | ELVN | Kintz Samuel PRESIDENT AND CEO | 12,000 | $1.12 | 1,465,428 (Direct) | View |
| 2024-04-11 Exercise | 2024-04-15 7:06 pm | N/A 2031-03-25 | Enliven Therapeutics Inc. | ELVN | Patel Anish CHIEF OPERATING OFFICER | 14,903 | $0 | 454,744 (Direct) | View |
| 2024-04-11 Exercise | 2024-04-15 7:06 pm | N/A N/A | Enliven Therapeutics Inc. | ELVN | Patel Anish CHIEF OPERATING OFFICER | 14,903 | $2.48 | 454,744 (Direct) | View |
| 2024-04-11 Exercise | 2024-04-15 7:06 pm | N/A 2030-06-16 | Enliven Therapeutics Inc. | ELVN | Lyssikatos Joseph P CHIEF SCIENTIFIC OFFICER | 30,000 | $0 | 1,347,585 (Direct) | View |
| 2024-04-11 Exercise | 2024-04-15 7:06 pm | N/A N/A | Enliven Therapeutics Inc. | ELVN | Lyssikatos Joseph P CHIEF SCIENTIFIC OFFICER | 30,000 | $1.12 | 1,347,585 (Direct) | View |
| 2024-04-11 Exercise | 2024-04-15 7:05 pm | N/A 2030-06-16 | Enliven Therapeutics Inc. | ELVN | Kintz Samuel PRESIDENT AND CEO | 47,709 | $0 | 1,477,428 (Direct) | View |
| 2024-04-11 Exercise | 2024-04-15 7:05 pm | N/A N/A | Enliven Therapeutics Inc. | ELVN | Kintz Samuel PRESIDENT AND CEO | 47,709 | $1.12 | 1,477,428 (Direct) | View |
| 2024-04-11 Exercise | 2024-04-15 7:04 pm | N/A 2031-08-02 | Enliven Therapeutics Inc. | ELVN | Hohl Benjamin CHIEF FINANCIAL OFFICER | 14,000 | $0 | 225,370 (Direct) | View |
| 2024-04-11 Exercise | 2024-04-15 7:04 pm | N/A N/A | Enliven Therapeutics Inc. | ELVN | Hohl Benjamin CHIEF FINANCIAL OFFICER | 14,000 | $2.48 | 225,370 (Direct) | View |
| 2024-04-11 Exercise | 2024-04-15 7:02 pm | N/A 2031-06-17 | Enliven Therapeutics Inc. | ELVN | Collins Helen Louise CHIEF MEDICAL OFFICER | 20,000 | $0 | 267,084 (Direct) | View |
| 2024-04-11 Exercise | 2024-04-15 7:02 pm | N/A N/A | Enliven Therapeutics Inc. | ELVN | Collins Helen Louise CHIEF MEDICAL OFFICER | 20,000 | $2.48 | 267,084 (Direct) | View |
| 2024-04-10 Exercise | 2024-04-12 6:23 pm | N/A 2028-10-19 | Enliven Therapeutics Inc. | ELVN | Ballal Rahul D. Director | 67,000 | $0 | 146,903 (Direct) | View |
| 2024-04-10 Exercise | 2024-04-12 6:23 pm | N/A N/A | Enliven Therapeutics Inc. | ELVN | Ballal Rahul D. Director | 62,420 | $12.6 | 146,903 (Direct) | View |
| 2024-04-11 Exercise | 2024-04-12 6:23 pm | N/A N/A | Enliven Therapeutics Inc. | ELVN | Ballal Rahul D. Director | 4,580 | $19.68 | 146,903 (Direct) | View |
| 2024-04-08 Option Award | 2024-04-10 8:39 pm | N/A 2034-04-08 | Enliven Therapeutics Inc. | ELVN | Kunkel Lori Anne Director | 37,882 | $0 | 37,882 (Direct) | View |
Ownership | 2024-04-10 8:37 pm | N/A N/A | Enliven Therapeutics Inc. | ELVN | Kunkel Lori Anne Director | 0 | $0 | 65,625 (Direct) | View |
| 2024-04-04 Exercise | 2024-04-08 8:40 pm | N/A 2028-10-19 | Enliven Therapeutics Inc. | ELVN | Ballal Rahul D. Director | 3,485 | $0 | 84,761 (Direct) | View |
| 2024-04-04 Exercise | 2024-04-08 8:40 pm | N/A N/A | Enliven Therapeutics Inc. | ELVN | Ballal Rahul D. Director | 3,485 | $12.6 | 84,761 (Direct) | View |
| 2024-04-01 Exercise | 2024-04-03 9:32 pm | N/A 2028-10-19 | Enliven Therapeutics Inc. | ELVN | Ballal Rahul D. Director | 3,237 | $0 | 104,674 (Direct) | View |
| 2024-04-01 Exercise | 2024-04-03 9:32 pm | N/A N/A | Enliven Therapeutics Inc. | ELVN | Ballal Rahul D. Director | 3,143 | $5.52 | 104,674 (Direct) | View |
| 2024-04-01 Exercise | 2024-04-03 9:32 pm | N/A N/A | Enliven Therapeutics Inc. | ELVN | Ballal Rahul D. Director | 94 | $12.6 | 104,674 (Direct) | View |
| 2024-04-01 Exercise | 2024-04-03 9:30 pm | N/A 2030-06-16 | Enliven Therapeutics Inc. | ELVN | Lyssikatos Joseph P CHIEF SCIENTIFIC OFFICER | 12,000 | $0 | 1,377,585 (Direct) | View |
| 2024-04-01 Exercise | 2024-04-03 9:30 pm | N/A N/A | Enliven Therapeutics Inc. | ELVN | Lyssikatos Joseph P CHIEF SCIENTIFIC OFFICER | 12,000 | $1.12 | 1,377,585 (Direct) | View |
| 2024-03-27 Exercise | 2024-03-29 5:59 pm | N/A 2031-08-02 | Enliven Therapeutics Inc. | ELVN | Hohl Benjamin CHIEF FINANCIAL OFFICER | 3,250 | $0 | 239,370 (Direct) | View |
| 2024-03-27 Exercise | 2024-03-29 5:59 pm | N/A N/A | Enliven Therapeutics Inc. | ELVN | Hohl Benjamin CHIEF FINANCIAL OFFICER | 3,250 | $2.48 | 239,370 (Direct) | View |
| 2024-03-25 Exercise | 2024-03-27 5:03 pm | N/A 2030-06-15 | Enliven Therapeutics Inc. | ELVN | Kintz Samuel PRESIDENT AND CEO | 12,000 | $0 | 1,525,137 (Direct) | View |
| 2024-03-25 Exercise | 2024-03-27 5:03 pm | N/A N/A | Enliven Therapeutics Inc. | ELVN | Kintz Samuel PRESIDENT AND CEO | 12,000 | $1.12 | 1,525,137 (Direct) | View |
| 2024-03-20 Exercise | 2024-03-22 7:46 pm | N/A 2032-01-27 | Enliven Therapeutics Inc. | ELVN | Ballal Rahul D. Director | 13,278 | $0 | 41,912 (Direct) | View |
| 2024-03-20 Exercise | 2024-03-22 7:46 pm | N/A N/A | Enliven Therapeutics Inc. | ELVN | Ballal Rahul D. Director | 13,278 | $5.52 | 41,912 (Direct) | View |
| 2024-02-29 Exercise | 2024-03-04 5:55 pm | N/A 2030-06-15 | Enliven Therapeutics Inc. | ELVN | Lyssikatos Joseph P CHIEF SCIENTIFIC OFFICER | 12,000 | $0 | 1,389,585 (Direct) | View |
| 2024-02-29 Exercise | 2024-03-04 5:55 pm | N/A N/A | Enliven Therapeutics Inc. | ELVN | Lyssikatos Joseph P CHIEF SCIENTIFIC OFFICER | 12,000 | $1.12 | 1,389,585 (Direct) | View |
| 2024-02-27 Exercise | 2024-02-29 5:27 pm | N/A 2031-08-02 | Enliven Therapeutics Inc. | ELVN | Hohl Benjamin CHIEF FINANCIAL OFFICER | 3,250 | $0 | 242,620 (Direct) | View |
| 2024-02-27 Exercise | 2024-02-29 5:27 pm | N/A N/A | Enliven Therapeutics Inc. | ELVN | Hohl Benjamin CHIEF FINANCIAL OFFICER | 3,250 | $2.48 | 242,620 (Direct) | View |
| 2024-02-26 Exercise | 2024-02-28 5:14 pm | N/A 2030-06-15 | Enliven Therapeutics Inc. | ELVN | Kintz Samuel PRESIDENT AND CEO | 12,000 | $0 | 1,537,137 (Direct) | View |
| 2024-02-26 Exercise | 2024-02-28 5:14 pm | N/A N/A | Enliven Therapeutics Inc. | ELVN | Kintz Samuel PRESIDENT AND CEO | 12,000 | $1.12 | 1,537,137 (Direct) | View |
| 2024-02-13 Option Award(A) | 2024-02-20 7:35 pm | N/A 2034-02-13 | Enliven Therapeutics Inc. | ELVN | Phillips Andrew John Director | 23,364 | $0 | 23,364 (Direct) | View |
| 2024-02-13 Option Award(A) | 2024-02-20 7:32 pm | N/A 2034-02-13 | Enliven Therapeutics Inc. | ELVN | Heyman Richard A. Director | 29,205 | $0 | 29,205 (Direct) | View |
| 2024-02-13 Option Award(A) | 2024-02-20 7:30 pm | N/A 2034-02-13 | Enliven Therapeutics Inc. | ELVN | Gupta Rishi Director 10% Owner | 23,364 | $0 | 23,364 (Direct) | View |
| 2024-02-13 Option Award(A) | 2024-02-20 7:27 pm | N/A 2034-02-13 | Enliven Therapeutics Inc. | ELVN | Derynck Mika K Director | 23,364 | $0 | 23,364 (Direct) | View |
| 2024-02-13 Option Award(A) | 2024-02-20 7:26 pm | N/A 2034-02-13 | Enliven Therapeutics Inc. | ELVN | Bauer Jake Director | 23,364 | $0 | 23,364 (Direct) | View |
| 2024-02-13 Option Award(A) | 2024-02-20 7:24 pm | N/A 2034-02-13 | Enliven Therapeutics Inc. | ELVN | Ballal Rahul D. Director | 23,364 | $0 | 23,364 (Direct) | View |
| 2024-02-13 Option Award | 2024-02-15 9:04 pm | N/A 2034-02-12 | Enliven Therapeutics Inc. | ELVN | Phillips Andrew John Director | 16,835 | $0 | 16,835 (Direct) | View |
| 2024-02-13 Option Award | 2024-02-15 9:02 pm | N/A 2034-02-12 | Enliven Therapeutics Inc. | ELVN | Patel Anish CHIEF OPERATING OFFICER | 185,000 | $0 | 185,000 (Direct) | View |
| 2024-02-13 Option Award | 2024-02-15 9:00 pm | N/A 2034-02-12 | Enliven Therapeutics Inc. | ELVN | Lyssikatos Joseph P CHIEF SCIENTIFIC OFFICER | 185,000 | $0 | 185,000 (Direct) | View |
| 2024-02-13 Option Award | 2024-02-15 8:56 pm | N/A 2034-02-12 | Enliven Therapeutics Inc. | ELVN | Kintz Samuel PRESIDENT AND CEO | 410,000 | $0 | 410,000 (Direct) | View |
| 2024-02-13 Option Award | 2024-02-15 8:54 pm | N/A 2034-02-12 | Enliven Therapeutics Inc. | ELVN | Hohl Benjamin CHIEF FINANCIAL OFFICER | 185,000 | $0 | 185,000 (Direct) | View |
| 2024-02-13 Option Award | 2024-02-15 8:52 pm | N/A 2034-02-12 | Enliven Therapeutics Inc. | ELVN | Heyman Richard A. Director | 21,043 | $0 | 21,043 (Direct) | View |
| 2024-02-13 Option Award | 2024-02-15 8:50 pm | N/A 2034-02-12 | Enliven Therapeutics Inc. | ELVN | Gupta Rishi Director 10% Owner | 16,835 | $0 | 16,835 (Direct) | View |
| 2024-02-13 Option Award | 2024-02-15 8:48 pm | N/A 2034-02-12 | Enliven Therapeutics Inc. | ELVN | Derynck Mika K Director | 16,835 | $0 | 16,835 (Direct) | View |
| 2024-02-13 Option Award | 2024-02-15 8:46 pm | N/A 2034-02-12 | Enliven Therapeutics Inc. | ELVN | Collins Helen Louise CHIEF MEDICAL OFFICER | 185,000 | $0 | 185,000 (Direct) | View |
| 2024-02-13 Option Award | 2024-02-15 8:44 pm | N/A 2034-02-12 | Enliven Therapeutics Inc. | ELVN | Bauer Jake Director | 16,835 | $0 | 16,835 (Direct) | View |